Total Hip ArthroplastyNCT05848024
EBRA Study AMISTEM-C FR
An observational study of Total Hip Arthroplasty, run by Medacta International SA at 1 site in France.
Trial summary
Primary objective: Evaluate femoral stem migration Secondary objective: Evaluate the performance of AMIStem H Proximal Coating at 10 years after surgery; assessment of functional recovery; radiological evaluation; reporting of complications Scores collected: HHS, OHS, PMA, UCLA Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Total Hip Arthroplasty
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- 8 Feb 2017to Feb 2029
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with a disease (primary coxarthrosis, inflammatory arthritis of the hip, necrosis of the femoral head, etc.) requiring a total hip replacement and who will receive an AMIStem® C cemented femoral stem. Patients will be able to participate in other non-interventional research during the study.
The inclusion criteria are:
- Patient with a disease (primary coxarthrosis, inflammatory arthritis of the hip, necrosis of the femoral head...) requiring the placement of a total hip prosthesis.
- Patient who will receive an AMIStem® C cemented femoral stem.
- Patient willing to comply with the study requirements
- Patient who has signed the information letter agreeing to the processing of their data in the clinical evaluation
- Patient affiliated to a social security system
- Patients aged 18 to 85 years
The criteria for non-inclusion are:
- Participation in biomedical research
- Minor patients
- Protected adult patients
- Vulnerable persons according to article L1121-6 of the Public Health Code
- Pregnant or breastfeeding women
- Patients unable to formulate their non-opposition
- Patient refusing collection of personal data
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prospective, Single-Center, Non-Controlled, Non-Randomized, Open Study Evaluating the Performance and Stability of Amistem® C
Primary objective: Evaluate femoral stem migration Secondary objective: Evaluate the performance of AMIStem H Proximal Coating at 10 years after surgery; assessment of functional recovery; radiological evaluation; reporting of complications
Scores collected:
HHS, OHS, PMA, UCLA
Read the detailed description
The main objective of the study was to evaluate the migration and performance of the AMIStem® C femoral stem at 10 years follow-up.
The primary endpoint is the measurement of femoral component migration by EBRA-FCA (The Ein Bild Roentgen Analyse-femoral component analysis, Innsbruck, Austria)
The secondary objectives of the study are:
Evaluate the performance of the AMIStem® C stem Evaluate the function of the operated hip To evaluate the quality of life To evaluate the safety of the AMIStem® C femoral stem Evaluate the postoperative stability and fixation of the hip prosthesis
- Conditions
- Total Hip Arthroplasty
What is being measured
The primary outcome is the main question the study is designed to answer.
Assess the femoral stem migration
The primary endpoint is the measurement of femoral component migration by EBRA-FCA software (The Ein Bild Roentgen Analyse-femoral component analysis, Innsbruck, Austria) with an accuracy of ± 1.5 mm (95% percentile), a specificity of 100% and a sensitivity of 78% for the detection of a migration of more than 1.0 mm, referring to the RSA method. The EBRA-FCA method is based on the detection of 19 points on the bony femur and the femoral component, as well as two lines to determine the axis of the implant on successive radiographs of the front pelvis. The correction of the radiological enlargement is performed based on the known diameter of the prosthetic femoral component. Lengths are measured from anatomical reference points to ensure comparability of the radiographs. The change in the distance between the top of the greater trochanter and the shoulder of the prosthesis is used to measure the migration of the femoral component.
Measured: 2 years
Secondary outcomes (6)
Assess the AMIStem C performance at 10 years
The survival rate according to a Kaplan Meier curve. The Kaplan-Meier method calculates the survival of the prosthesis by measuring the fraction of living subjects during a period after the procedure. Each time an expected event occurs (revision of the prosthesis, patients lost to follow-up, death, etc.), the probability of implant survival changes. This information is used to estimate the performance of the prosthesis.
During the study, the number of stem revisions and the number of patients who died or were lost to follow-up will be collected to calculate the probability of survival. The time of occurrence will be recorded for each event.
Measured: 10 years
Assess the functionality of the operated hip
Evaluation of the Harris Hip Score The Harris Hip Score (HHS) items include an analysis of the operated hip according to pain, function, mobility, stability and deformity analysis. The Harris Hip Score will be used to assess the patient's subjective and objective improvement in the above criteria. The usefulness of this score has been studied to estimate the clinical results after THR, it is a reference score in the field of orthopedics.
The Harris hip score is scored from 0 (worst functional outcome and maximum pain) to 100 points (best functional outcome and least pain).
Measured: pre-op, 7 days, 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years and 10 years
Assess the Quality of Life of patients
Merle d'Aubigné functional score The Postel and Merle d'Aubigné (PMA) score: a method for grading the functional value of the hip form a minimum of 0 to a maximum of 18 points.
Measured: pre-op, 7 days, 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years and 10 years
Assess the security of AMIStem C and collect complications
Collection of intra- and postoperative complications (infection, loosening,etc)
Measured: pre-op, 7 days, 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years and 10 years
Assess the postoperative stability and fixation of AMIStem C
Collection of Oxford Hip Score: It is a score composed of 12 questions evaluating the function and pain of the hip before and after arthroplasty.
The scores for the 0-48 scale can be interpreted as follows[6]:
Score 0 to 19 May indicate severe hip arthritis. It is highly likely that you may well require some form of surgical intervention, contact your family physician for a consult with an orthopaedic surgeon.
Score 20 to 29 May indicate moderate to severe hip arthritis. See your family physician for an assessment and x-ray. Consider a consult with an orthopaedic surgeon.
Score 30 to 39 May indicate mild to moderate hip arthritis. Consider seeing your family physician for an assessment and possible x-ray. You may benefit from non-surgical treatment, such as exercise, weight loss, and/ or anti-inflammatory medication.
Score 40 to 48 May indicate satisfactory joint function. May not require any formal treatment.
Measured: pre-op, 7 days, 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years and 10 years
Radiological analysis
-Standard X-ray to identify radiolucencies and endosteal cavitations
Measured: pre-op, 7 days, 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years and 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2023
- Study start8 Feb 2017
- Primary completionFeb 2027 (estimated)
- Study completionFeb 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Total Hip ArthroplastyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medacta International SA
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Donatien Bocquet, Principal investigator, Hôpital privé Arras Les Bonnettes 2 rue du docteur Forgeois 62012 Arras
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05848024
- Sponsor's protocol ID
- P01.001.10
- Status last verified
- Sep 2026
- First submitted
- 21 Apr 2023
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No